MetaFines Corp. , was established in 2018 and is developing a “low-toxic cancer metabolism drugs” through the expansion and reorganization of indications for off-label drugs for incurable and terminal cancers. We are currently preparing to enter the domestic IND(Investigational New Drug) based on 'ASCA101', which is designed to inhibit cancer growth and block metastasis by simultaneously inducing the blocking of major energy sources of cancer and improving the tumor environment.

Besides, focusing on the leading substance in the form of injections, “ASCA101,” we are developing another formulations that are convenient for patients to take, such as oral and subcutaneous injections. And, we are carrying forward the development of treatments for cancer fatigue syndrome supplement, terminal cancer relief supplement and other metabolic diseases drug.